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 ABSTRACT 
Schizophrenia is a spectrum of disorders defined by abnormalities in one or more areas 
including delusions, hallucinations, disorganized thinking or speech, grossly disorganized or 
abnormal motor behaviors including catatonia and other negative symptoms (American 
Psychology Association, 2013).  Schizophrenia is inherited on autosomal chromosome 8p12. 
Neuregulin 1 (NRG1), an epithelial growth factor protein, located at 8p12, has been identified 
as being a nucleotide variation of the single-nucleotide polymorphism (SNP), rs833497 located 
on chromosome 18q21.1 that is associated with schizophrenia. 
INTRODUCTION 
Schizophrenia is spectrum of psychiatric and schizotypal disorders. The 5th edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-V), characterizes schizophrenia 
spectral disorders as being defined by abnormalities in one or more areas including delusions, 
hallucinations, disorganized thinking or speech, grossly disorganized or abnormal motor 
behaviors including catatonia and other negative symptoms (American Psychology Association, 
2013). Sufferers have an altered perception of reality and experience symptoms for a significant 
period lasting longer than one month. Schizophrenia was first distinguished from “common 
madness” in 1887 by a German physician, Emile Kraepelin, who described the disorder as 
“dementia praecox”. According to the National Institute of Mental Health, approximately 1% of 
all U.S adults have schizophrenia. 
 There are two types of schizophrenics differentiated by the symptoms they exhibit. A 
person with Type I schizophrenia is said to be producing positive symptoms which are a 
combination of hallucinations, delusions bizarre behavior and racing thoughts. A person with 
Type II would experience what are known as negative symptoms which include apathy, a lack of 
emotion, poor social functioning and catatonia (Comer, 2009).  
 
GENETIC BACKGROUND 
There are many debates among scientist about whether or not environmental or genetic 
factors play a role in the cause of schizophrenia.  However, many research studies have 
revealed that there is in fact an inherited element of the diseases. In fact, if one identical twin is 
diagnosed with schizophrenia there is about a 50% change that the other twin will also be 
diagnosed (Gottesman, 1991). A notable association study between the dymeclin (DYM) gene 
and schizophrenia in the Japanese population revealed that each copy of a C at rs833497, in the 
DYM gene was associated with 1.16 times more likeliness of schizophrenia (Yazaki, et al., 2010). 
The DYM gene is associated with the Golgi apparatus, which packages proteins after they are 
synthesized by the rough endoplasmic reticulum of a cell, and cellular vesicle trafficking, which 
moves proteins packaged by the Golgi apparatus and other substances across the cell 
membrane to specific locations in the plasma membrane and is in chromosome 18q21.1 
(Yazaki, et al., 2010) (Figure 1).   
 
Figure 1: Chromosome Location of DYM gene 18q21.1 (Created using the National Center for 
Biotechnology Information’s Genomic Decoration Page)  
This means that schizophrenia has an autosomal inheritance and the single-nucleotide 
polymorphism (SNP), rs833497 is associated with schizophrenia. In the same study a meta-
analysis of genetic association, on family studies was conducted which revealed Neuregulin 1 
(NRG1) as being a nucleotide variation in Golgi apparatus genes with schizophrenia (Yazaki, et 
al., 2010).  A case-control association study of 478 Icelandic schizophrenic patients mapped 
schizophrenia to 8p and identified NRG1 as a schizophrenia gene (Gulcher, et al., 2003). NRG1 is 
an epithelial growth factor protein that regulates activity-dependent synaptic plasticity, 
stimulates glial development, epithelial differentiation, and effects neuro-signaling.  NRG1 is 
involved in many aspects of brain development and is located in chromosome 8p12 (Figure 2). 
 
Figure 2: Chromosome Location of NRG1 8p12 (Created using the National Center for 
Biotechnology Information’s Genomic Decoration Page) 
 NRG1 interacts with cells through the receptor tyrosine-protein kinase erbB-4 (ErbB4) 
receptor, which is a part of the epidermal growth factor receptor family (Pitcher, et al., 2010). 
This family of genes consists of NRG1, NRG2, NRG3, and NRG4. They bind to and activate the 
ErbB family of receptor tyrosine kinases (ErbB1, ErbB2, ErbB3, ERbB4) (Pitcher, et al., 2010). The 
NRG1-ErB4 signal suppresses the kinase activity of proto-oncogene tyrosine-protein kinase Src 
(Src), which phosphorylates N-methyl-D-aspartate receptor (NMDAR) subunits 2a and 2b, which 
control synaptic plasticity and memory function (Pitcher, et al., 2010). This binding is more 
frequent in an individual with schizophrenia leading to overactive signaling which suppresses 
and depletes NMDAR leading to low glutamate levels which are associated with low energy 
levels, memory loss and depression (Pitcher, et al., 2010). Test studies conducted on mice 
mutant for NRG1 or ErB4, displayed behavior abnormalities consistent with schizophrenic 
models (Gulcher, et al., 2003). 
 
Figure 3: NRG1/NMDAR pathway 
 
 
TREATMENT  
There are currently no available treatments for schizophrenia on a genetic level. There is 
also no cure of any kind for schizophrenia. Anti-psychotic medications have been used since the 
1950’s as a way to attempt to control symptoms associated with schizophrenia along with 
various types of therapies. Based on the current available research on the genetic components 
of schizophrenia I believe finding a cure lies in understanding why the NGR1-ErbB-4 binds over-
actively producing signals that inhibit src from phosphorylating NMDAR in an individual with 
schizophrenia. If scientist could figure out how to either 1. How to reduce the NGR1-ErbB-4 
binding or 2. Reactivate NMDAR, through other means of phosphorylation then a cure may not 
be too far away. Because NRG1 plays such a big role in brain development, its effect on the less 
significant processes may lead to how schizophrenia is formulated within the brain.   
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